Author: Eagle Biosciences

The Genetic Analysis GA-Map® Dysbiosis Text Lx has been validated on the Luminex MAGPIX system. The company proudly announced the successful completion of validation at the beginning of February. Previously, the GA-Map Dysbiosis Test Lx was only validated for the Luminex 200.

GA-Map Dysbiosis Test Lx Principle

The GA-Map Dysbiosis Test Lx is a tool that allows mapping of the intestinal microbiota profile for a selected set of bacteria in a sample. The GA-Map Dysbiosis Test is based on advances in DNA profiling using probes targeting variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by professor Knut Rudi of the Norwegian University of Life Sciences (​NMBU) (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine the microbiota profile in the sample. The algorithm is incorporated in the GA-Map Dysbiosis Analyzer software that accompanies the test.

Luminex MAGPIX Validation

The MAGPIX® instrument is the most affordable instrument of the Luminex’s xMAP instruments. The MAGPIX system is already a widely used platform and a large number of laboratories have already installed this system for performing other tests.

The human microbiome market is accelerating both in terms of evidence-based research and pharma products launched. The market’s need for a validated microbiome test is growing with this market. Thus, the news today that more labs can start microbiome testing with GA-Map on MAGPIX will fuel this growth and create more research opportunities.

Check out the full press release here.

If you have any questions about the GA-Map Dysbiosis Test Lx or our other offerings, contact us here.

New data suggests the Cov19 FluoBolt-DAT detects antibodies against the new Omicron variant.

Quantitative Duplex Antibody Test (DAT) for antibodies to SARS-CoV-2

The Cov19 FluoBolt-DAT allows the simultaneous and quantitative measurement of antibodies against the S1 RBD AND Nucleocapsid antigen of SARS-CoV-2. In contrast, other antibody assays detect all antibodies generated against the S1- OR NC-protein. This test, however, is epitope specific. It detects immune-dominant antibodies species, i.e. the most important antibodies generated by either vaccination or infection.

This is demonstrated by the fact, that it detects anti-S1RBD against all dominant virus variants identified so far. The data indicates (see chart below) that the S1RBD part of the Cov19 FluoBolt-DAT assay detects the immune-dominant epitope and that individuals testing S1RBD -positive in the FluoBolt-DAT test have developed significant amounts of antibodies against this epitope. Therefore, they might be well protected against all current and future SARS-CoV-2 variants

Benefits of the Cov19 FluoBolt-Dat Assay:

• • Only One Single Measurement Required
  • Small Sample Size Need – 10 uL
  • Results within 60 minutes

  Other Cov19 FluoBolt-DAT Resources:

  • Quick Guide
  • New Product Announcement
  • Literature

  ---

  Check out our other COVID-19 assays here.

  If you have any questions about this kit or our other offerings, contact us here.

This week Eagle Biosciences is highlighting a revolutionary test in the microbiome industry. The GA-map® Dysbiosis Test Lx was developed by Genetic Analysis in Norway. The GA-map ® is a tool that allows mapping of the intestinal microbiota profile for a selected set of bacteria in a sample. The test is based on advances in DNA profiling using probes targeting variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by professor Knut Rudi of the Norwegian University of Life Sciences (​NMBU) (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine the microbiota profile in the sample. The algorithm is incorporated in the GA-map® Dysbiosis Analyzer software that accompanies the test.

Check out this video for a quick overview of the GA-map ® Dysbiosis Test Lx Platform equipment and techniques.

If you have any questions about the GA-map® Dysbiosis Test Lx or our other offerings contact us here.

Polystreptavidin R (Polystrept R) reagent is for the surface coating of plastics, membranes, beads and etc. with maximum biotin binding capacity. It improves the signal-noise-relation in testing and can help save on material costs.

About Polystreptavidin R (Polystrept R)

Polystrept R is a chemically modified polymerized Streptavidin characterized by an extraordinary high Biotin binding capacity. Polystrept R coatings on solid phases offer a universal immobilization principle for the detection and analysis of proteins, peptides, PCR-fragments, haptens etc., which must be present in a biotinylated form. Coatings made of Polystreptavidin R combine the excellent binding capacity with a high chemo and thermo stability and a long shelf life. It is suitable for coatings of membranes, beads, biochips, plastics etc.

Learn about the benefits of using Polystrept R in your research in this video from Biotez!

Why use streptavidin-coated microplates and Polystrept R with lateral flow test strips??

• Convenient method for a uniform and stable immobilization of biotinylated molecules
• Immobilization of Biomolecules on solid phases in a directed manner, while avoiding or minimizing denaturation
• Ready-to-use, no washing or blocking steps required
• High signal-to-noise ratio
• Low nonspecific binding
• Long shelf life
• Lower reagent consumption and especially enormous cost savings with lateral flow test stripes

Related Posts

• New Product Announcement: Polystreptavidin R (Polystrept R) Extraordinary high Biotin binding capacity

If you have any questions about Polystreptavidin R or our other offerings, contact us here.